Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence study of LZM008 versus Actemra in moderate to severe active rheumatoid arthritis
ChiCTR2300067652Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of LZM008 in rheumatoid arthritis (RA) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Percentage of participants achieving ACR20 at week 24. Started Jul 2019; status: completed.
02
Drugs
LZM008
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2300067652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067652.